Terns Pharmaceuticals Inc
$ 52.71
0.06%
15 Apr - close price
- Market Cap 6,071,899,000 USD
- Current Price $ 52.71
- High / Low $ 52.76 / 52.67
- Stock P/E N/A
- Book Value 8.96
- EPS -1.03
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.14 %
- 52 Week High 53.19
- 52 Week Low 2.23
About
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other chronic liver diseases. The company is headquartered in Foster City, California.
Analyst Target Price
$53.62
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2026-03-31 | 2025-11-10 | 2025-08-05 | 2025-05-12 | 2025-03-12 | 2024-11-12 | 2024-08-05 | 2024-05-13 | 2024-03-14 | 2023-11-14 | 2023-08-08 |
| Reported EPS | -0.2395 | -0.24 | -0.27 | -0.26 | -0.26 | -0.24 | -0.28 | -0.31 | -0.3 | -0.29 | -0.42 | -0.25 |
| Estimated EPS | None | -0.2999 | -0.3021 | -0.2918 | -0.2702 | -0.3002 | -0.32 | -0.34 | -0.34 | -0.29 | -0.31 | -0.34 |
| Surprise | 0 | 0.0599 | 0.0321 | 0.0318 | 0.0102 | 0.0602 | 0.04 | 0.03 | 0.04 | 0 | -0.11 | 0.09 |
| Surprise Percentage | None% | 19.9733% | 10.6256% | 10.8979% | 3.775% | 20.0533% | 12.5% | 8.8235% | 11.7647% | 0% | -35.4839% | 26.4706% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TERN
2026-04-14 18:39:56
JP Morgan analyst Rodolfo Angele maintained an Overweight rating for Terns Pharmaceuticals (TERN) and raised its price target to $44.50 on April 14, 2026. Despite this optimistic outlook, the company has a GF Score™ of 34/100, indicating below-average performance potential, and significant insider selling has occurred in the past three months. Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on treatments for chronic diseases.
2026-04-10 20:09:35
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK) for $53.00 per share in cash. KSF is evaluating whether the consideration and the process leading to it are adequate, suspecting the offer might undervalue the company. Shareholders are encouraged to contact KSF if they believe the transaction undervalues Terns Pharmaceuticals or to discuss their legal rights.
2026-04-10 19:10:31
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK) for $53.00 per share in cash. KSF is scrutinizing the adequacy of the consideration and the process that led to the transaction, seeking to determine if it undervalues the Company. Shareholders concerned about the proposed sale are encouraged to contact KSF to discuss their legal rights, especially given the tender offer structure.
2026-04-10 19:10:31
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). The law firm is scrutinizing whether the proposed cash consideration of $53.00 per share for Terns shareholders and the underlying process are adequate, or if they undervalue the company. KSF encourages shareholders who believe the transaction undervalues the company to contact them to discuss their legal rights.
2026-04-09 13:39:47
Merck & Co. announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, at $53 per share in cash. This acquisition will add TERN-701, an oral candidate for chronic myeloid leukemia, to Merck's hematology portfolio, strengthening its oncology position and diversifying its therapeutic areas. The deal is expected to close in the second quarter of 2026.
2026-04-08 21:10:34
Merck & Co. lowered its offer to acquire Terns Pharmaceuticals from $61 to $53 per share after reviewing updated clinical trial data for Terns' lead drug, TERN-701. The updated data from the CARDINAL trial showed a lower major molecular response (MMR) achievement rate, which influenced Merck's negotiation strategy and also led another large pharmaceutical company to withdraw its competing bid. Despite the lower rate, Merck still considered the data compelling relative to asciminib and remains enthusiastic about the acquisition.
